布地奈德胶囊治疗哮喘效果怎么样

How effective are budesonide capsules in treating asthma? One study reported that an intermittent high-dose budesonide regimen was as effective as a daily low-dose regimen in reducing asthma exacerbations in preschool children with recurrent wheezing.

This is a multicenter, randomized, double-blind, parallel-group MIST (Maintenance and Intermittent Inhaled Corticosteroids in Children with Asthma) trial. The clinical trial included children aged 12 to 53 months who were modified API positive, had recurrent wheezing, and had ≥1 acute exacerbation in the past year but with low severity of injury (defined as infrequent use of albuterol and infrequent nighttime awakenings between exacerbations). All subjects first received pretreatment with nightly placebo doses of budesonide inhalation suspension for 2 weeks (run-in period) and albuterol if necessary, and then received 52 weeks (treatment period) of randomized treatment. The intermittent treatment group (n=139) received 1 mg budesonide inhalation suspension twice a day for 7 days after the respiratory disease was diagnosed; the daily treatment group (n=139) received 0.5 mg budesonide inhalation suspension every night.

The results showed that the incidence rates of asthma exacerbation in the daily treatment group and the intermittent treatment group were 0.97/(patient·year) and 0.95/(patient·year) respectively, and the relative incidence rate in the intermittent treatment group was 0.99. There were no significant differences in the time to the first exacerbation (HR, 0.97), the time to the second exacerbation (HR, 0.79) or the number of treatment failures between the two groups. There were also no significant differences in the prespecified secondary endpoints of respiratory disease and respiratory disease requiring prednisolone treatment, number of respiratory disease treatments, and time to first respiratory disease treatment. The incidence rates of non-serious adverse events and serious adverse events were also similar between the two groups, but the average cumulative exposure of budesonide in the intermittent treatment group was significantly smaller than that in the daily treatment group (45.7 mg vs. 149.9 mg).